Uveal melanoma (UM) is the most common primary malignant ocular tumour in adults, although its epidemiology in Central and Eastern Europe is unclear. This study aimed to analyse the incidence and all-cause mortality of UM in Hungary. This nationwide, retrospective, longitudinal study used data from the National Health Insurance Fund and included patients aged ≥18 years who were newly diagnosed with UM (ICD-10 C69.3 or C69.4) between 1 January 2012 and 31 December 2021. Age-standardised incidence and all-cause mortality rates were calculated using European Standard Population data from 2013. We identified 88 and 70 new patients with UM in 2012 and 2021, respectively, showing an almost stable trend. Age-standardised incidence rates varied between 6.40 and 10.96/1,000,000 person-years (PYs) during the analysed period. The highest age-standardised incidence was detected among men (13.38/1,000,000 PYs) in 2015. All-cause mortality decreased from 4.72/1,000,000 PYs to 0.79/1,000,000 PYs between 2012 and 2021. In conclusion, the UM incidence rate in Hungary is comparable to European incidence rates. The incidence did not markedly change, whereas all-cause mortality decreased during the study period, but this decline could not be attributed to improved treatment modalities for primary tumours and metastatic UM.
葡萄膜黑色素瘤是成人中最常见的原发性眼部恶性肿瘤，但其在中欧和东欧的流行病学特征尚不明确。本研究旨在分析匈牙利葡萄膜黑色素瘤的发病率与全因死亡率。这项全国性回顾性纵向研究采用国家健康保险基金数据，纳入2012年1月1日至2021年12月31日期间新确诊为葡萄膜黑色素瘤（ICD-10编码C69.3或C69.4）的18岁及以上患者。基于2013年欧洲标准人口数据计算年龄标准化发病率与全因死亡率。研究显示2012年与2021年分别新确诊88例和70例患者，发病率总体保持稳定。研究期间年龄标准化发病率波动于6.40-10.96/百万人年之间，其中2015年男性发病率最高（13.38/百万人年）。全因死亡率从2012年的4.72/百万人年下降至2021年的0.79/百万人年。结论表明，匈牙利葡萄膜黑色素瘤发病率与欧洲整体水平相当，研究期间发病率未见显著变化，而全因死亡率呈下降趋势，但该下降趋势不能归因于原发肿瘤及转移性葡萄膜黑色素瘤治疗方式的改进。
Incidence and Mortality of Uveal Melanoma in Hungary: A Nationwide Study
肿瘤(癌症)患者之家